Oligomerix is a biotechnology company focused on developing disease-modifying and treatment therapeutics for neurodegenerative diseases characterized by aberrant tau protein, including Alzheimer’s disease and rare tauopathies.

Oligomerix

Oligomerix, Inc | 867 followers on LinkedIn. Developing small molecule therapeutics targeting tau for rare neuro diseases and AD - clinical studies starting 2022 | Oligomerix is an emerging biotechnology company focused on developing disease-modifying therapeutics for neurodegenerative diseases characterized by aberrant tau protein ranging from rare tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer’s disease. With a focus on oral, small molecule, tau self-association inhibitors, Oligomerix seeks to develop therapies for Alzheimer’s disease and other dementias that are easy to administer and cost effective, and which are expected to significantly add to newly emerging high-cost therapeutic options such as the monoclonal antibody targeted against beta-amyloid that was recently approved by the U.S. FDA.

Chief Financial Officer at Oligomerix, Inc.

Bob Foerster

Scientist at Oligomerix Inc., NY USA

Dhruv Patel, Ph.D.

CEO and Head, Discovery & Strategy at OLIGOMERIX, Inc.

James Moe

Oligomerix, Inc

Viewport Meta

IPhone / Mobile Compatible

Euro

Google Tag Manager

Apple Mobile Web Clips Icon

Google Font API

Google Analytics

Content Delivery Network

WordPress

Global Site Tag

Chief Scientist

Eliot Davidowitz

Director, Chief Commercial Officer

Jack Pasini

CEO and Head, Discovery & Strategy

Lab Manager

Patricia Lopez

Engineering

Chaya Sussman

Mindy Hair

Business Management

William Erhart

Co-Founder, CEO and Head, Discovery & Strategy

Eliot J. Davidowitz

Co-Founder & Chief Scientist

Vic Micati

Chairman

East Coast Companies With Less Than $50M in Revenue (Top 10K)

East Coast Early Stage Companies With More Than $1M in Revenue

Companies With Fewer Than 10 Employees (Top 10K)

New York Early Stage Companies With Fewer Than 100 Employees

Oligomerix is a biopharmaceutical company founded in 2006 by co-founders Eliot J. Davidowitz and James Moe. The Company is exploiting its novel research  that allows rapid generation of stable amyloid oligomers as targets for drug discovery. These systems will enable target identification and validation, and drug discovery for Alzheimer's and other neurodegenerative diseases.

National Institute on Aging

Grant - Oligomerix

National Institutes of Health

Series B - Oligomerix

Small Business Innovation Research

Venture Round - Oligomerix

Series A - Oligomerix

Bronx

New York

United States

North America

Methods and compositions comprising tau oligomers

Oligomeric materials to enhance water splitting

Oligomerix and Feinstein Institutes publish preclinical data of Alzheimer's disease treatment

A small molecule inhibitor of tau self-association, currently in Phase 1 clinical trials, aimed at treating Alzheimer's disease and other tauopathies by preventing tau aggregation.

A series of small molecules designed to inhibit tau self-association, targeting the early stages of tau aggregation in neurodegenerative diseases.

Programs focused on developing biomarkers to complement tau-targeting therapeutics, aiding in the diagnosis and monitoring of neurodegenerative diseases.

HTML5

Lightbox

jQuery

Adobe Flash

GoDaddy Premium DNS

F5 NGINX

Vimeo

Apache Server

DigiCert

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 17, 2024 8:59 PM	35846c21
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 17, 2024 8:59 PM	dce55db7
crunchbase trigger	general	Nov 17, 2024 8:59 PM	14970e90
crunchbase profile	general	Nov 17, 2024 9:04 PM	55a3286c
li profile	general	Nov 17, 2024 8:59 PM	b3a814fe
translate crunchbase fundingrounds	general	Nov 17, 2024 9:30 PM	c2d26fed
peers	general	Nov 17, 2024 8:59 PM	e645e4b3
news basic	general	Nov 17, 2024 8:59 PM	5e8c5f01
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

OLIG

COM:OLIGOMERIX

Oligomerix